Search research articles
Contact Us
Filters
Showing results (111-120 of 120) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 120 results.
British Journal of Haematology
|
March 23, 1999
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life
M L Stead, J M Brown, G Velikova, et al.
European Journal of Haematology
|
August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)
N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology
|
January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)
P Gimsing, O W Bjerrum, E Brandt, et al.
Haemostasis
|
January 1, 1996
Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
J Kristensen, A Killander, E Hippe, et al.
Autoimmunity
|
January 1, 1991
Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases
U Feldt-Rasmussen, M Høier-Madsen, K Bech, et al.
Leukemia
|
June 1, 1991
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark
O P Hansen, J Pedersen-Bjergaard, J Ellegaard, et al.
Leukemia
|
January 1, 1997
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML
P de Nully Brown, T Hoffmann, O P Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2007
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K Cocks, D Cohen, F Wisløff, et al.
Medical Oncology (Northwood, London, England)
|
January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
N Gulbrandsen, F Wisløff, L Brinch, et al.
Blood
|
December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group
S Lenhoff, M Hjorth, E Holmberg, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 120) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 120 results.
British Journal of Haematology
|
March 23, 1999
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life
M L Stead, J M Brown, G Velikova, et al.
European Journal of Haematology
|
August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)
N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology
|
January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)
P Gimsing, O W Bjerrum, E Brandt, et al.
Haemostasis
|
January 1, 1996
Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
J Kristensen, A Killander, E Hippe, et al.
Autoimmunity
|
January 1, 1991
Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases
U Feldt-Rasmussen, M Høier-Madsen, K Bech, et al.
Leukemia
|
June 1, 1991
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark
O P Hansen, J Pedersen-Bjergaard, J Ellegaard, et al.
Leukemia
|
January 1, 1997
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML
P de Nully Brown, T Hoffmann, O P Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2007
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K Cocks, D Cohen, F Wisløff, et al.
Medical Oncology (Northwood, London, England)
|
January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
N Gulbrandsen, F Wisløff, L Brinch, et al.
Blood
|
December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group
S Lenhoff, M Hjorth, E Holmberg, et al.
Page
of 12